Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) Fabhalta is the only oral alternative complement pathway ...

At Novartis, we innovate, develop and operate on a vast scale. You can be part of it. Join our creative community of professionals and you will find opportunities to make an unprecedented impact – on ...

The long-term, exclusive pharmaceutical category agreement is designed to turn fans' passion for the game into a commitment to better health Novartis sports partnership covers the NFL's marquee health ...

Novartis works with the patient community around the world to discover new ways to improve and extend people’s lives. Novartis works closely with healthcare professionals around the world to support ...

Explore opportunities with Novartis and Sandoz below. For additional roles with Novartis Gene Therapies (formerly AveXis) visit the GTx Career Search.

Basel, March 7, 2025 – Novartis shareholders today agreed to the Board of Directors’ recommendations for all proposed resolutions at the company’s Annual General Meeting (AGM). A total of 1,693 ...

V Novartisu spodbujamo inovativnost in razvoj ter delujemo na številnih področjih. Tudi vi lahko postanete del tega, del naše zgodbe. Pridružite se naši ustvarjalni skupnosti strokovnjakov in našli ...

Phase III data demonstrated clinically meaningful 35.1% proteinuria reduction 6; also, a stabilization of estimated glomerular filtration rate (eGFR) – a key measure of kidney function – was observed ...